Clinical Trial Results: Renal Cell Cancer

Product Name: Avastin [bevacizumab]
Date of Report: 3/1/2007
Phase: III
A randomized, double-blind, phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a (Roferon) versus interferon alfa-2a and placebo as first line treatment administered to nephrectomised patients with metastatic clear cell renal cell carcinoma.

Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: II
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: II
A Study to Provide Patients Who Have Responded to Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) or Roferon-A (Interferon alfa-2a, Recombinant) in Prior Clinical Studies Continued Access to the Drug